Heparin for the treatment of thrombosis in preterm and term neonates

Olga Romantsik, Matteo Bruschettini, Simona Zappettini, Luca Antonio Ramenghi, Maria Grazia Calevo

Research output: Contribution to journalArticle

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).

Original languageEnglish
Article numberCD012185
JournalThe Cochrane database of systematic reviews
Volume2016
Issue number5
DOIs
Publication statusPublished - May 5 2016

Fingerprint

Heparin
Thrombosis
Newborn Infant
Low Molecular Weight Heparin
Protein S Deficiency
Inborn Genetic Diseases
Thrombophilia
Therapeutics
Protein C
Birth Weight
Gestational Age
Placebos
Morbidity
Safety
Mutation
Mortality

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Cite this

Heparin for the treatment of thrombosis in preterm and term neonates. / Romantsik, Olga; Bruschettini, Matteo; Zappettini, Simona; Ramenghi, Luca Antonio; Calevo, Maria Grazia.

In: The Cochrane database of systematic reviews, Vol. 2016, No. 5, CD012185, 05.05.2016.

Research output: Contribution to journalArticle

@article{161df180eb1e45c39158367e6230ee11,
title = "Heparin for the treatment of thrombosis in preterm and term neonates",
abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).",
author = "Olga Romantsik and Matteo Bruschettini and Simona Zappettini and Ramenghi, {Luca Antonio} and Calevo, {Maria Grazia}",
year = "2016",
month = "5",
day = "5",
doi = "10.1002/14651858.CD012185",
language = "English",
volume = "2016",
journal = "Cochrane Database of Systematic Reviews",
issn = "1361-6137",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Heparin for the treatment of thrombosis in preterm and term neonates

AU - Romantsik, Olga

AU - Bruschettini, Matteo

AU - Zappettini, Simona

AU - Ramenghi, Luca Antonio

AU - Calevo, Maria Grazia

PY - 2016/5/5

Y1 - 2016/5/5

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To assess whether heparin treatment (both UFH and LMWH) in preterm and term newborn infants with diagnosed thrombosis reduces the rate of mortality and morbidity. The intervention will be compared to placebo or no treatment. In addition, the safety of heparin therapy (both UFH and LMWH) will be assessed for potential harms. Subgroup analyses will be performed regarding gestational age, birth weight, mode of thrombus diagnosis, presence of central line, positive family history for genetic disorders (thrombophilia, deficiency of protein S and protein C, MTHFR mutation), route of heparin administration, type of heparin used, and location of thrombus (see Subgroup analysis and investigation of heterogeneity).

UR - http://www.scopus.com/inward/record.url?scp=84965048628&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84965048628&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD012185

DO - 10.1002/14651858.CD012185

M3 - Article

VL - 2016

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1361-6137

IS - 5

M1 - CD012185

ER -